The Food and Drug Administration (FDA) has cleared Lumos Labs’ prescription digital therapeutic, LumosityRx, to improve attention function in adults aged 22 to 55 years with primarily inattentive or combined-type…
The Food and Drug Administration (FDA) has cleared Lumos Labs’ prescription digital therapeutic, LumosityRx, to improve attention function in adults aged 22 to 55 years with primarily inattentive or combined-type…